In 2013, the United States and the European Union launched TTIP, which could end up being the most ambitious trade agreement in history.  Both sides recognized that in most areas, “traditional” trade barriers such as import tariffs and quotas are the impediments to transatlantic trade and investment, but rather “behind the border” issues, such as the lack of alignment or unnecessary duplication among regulatory systems.  This panel will examine how the TTIP could fundamentally alter the prospects for biotechnology, by converging regulatory regimes, addressing bureaucratic barriers and lack of transparency, and expediting product approvals.

Session ID: 2572

myBIO Chatter
Educational Topics